Prevention of type 2 diabetes
The DOI matches its Crossref record; 72 of the 72 references it cites were found in a registry or an index.
Abstract
Diabetes is a major public health problem that is approaching epidemic proportions in our society and worldwide. Cardiovascular disease is the major cause of morbidity and mortality in people with diabetes. Control of cardiovascular disease risk factors is achieved only in a minority of patients. Given the magnitude of the problem and the seriousness of diabetes complications, prevention appears to be a logical approach to curb the rising prevalence of the disease. Interventions such as lifestyle modifications and the use of metformin and acarbose have been shown in randomized prospective trials to prevent diabetes in high-risk patients. Other interventions are currently being examined in large prospective studies. It is likely that one or a combination of these approaches will make diabetes prevention a reality in the near future.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Data from various studies demonstrate that even a modest loss of 5–10% of initial body weight may significantly improve glycemic control, hyperinsulinemia and other metabolic abnormalities [13,14].”
From The case for low carbohydrate diets in diabetes management (2005) · cites this paper as [14]
In the citing paper
“Weight control, per se, is thus a critical component for achieving glycemic control, improving insulin resistance and modifying CVD risk in patients with diabetes and insulin resistance as well as for diabetes prevention [14,17].”
From The case for low carbohydrate diets in diabetes management (2005) · cites this paper as [14]
In the citing paper
“and LoCHO diets have been reported to lower postprandial glucose levels directly and indirectly by way of weight loss and may have beneficial effects on CVD risk factors [4,14].”
From The case for low carbohydrate diets in diabetes management (2005) · cites this paper as [14]
Citations
Cites
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin
(2002) · New England Journal of Medicine · doi:10.1056/nejmoa012512 · Cited by 19,011
Ahmed, A., Jorna, T., & Bhandari, S. (2016) · Nephron · doi:10.1159/000447068 · Cited by 11,717
Tuomilehto, J., Lindström, J., Eriksson, J. G., Valle, T. T., Hämäläinen, H., Ilanne-Parikka, P., Keinänen-Kiukaanniemi, S., Laakso, M., Louheranta, A., Rastas, M., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200105033441801 · Cited by 10,873
Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus
The Expert Committee on the Diagnosis and Classification of Diabetes Mellitus* (2002) · Diabetes Care · doi:10.2337/diacare.25.2007.s5 · Cited by 10,338
(2000) · New England Journal of Medicine · doi:10.1056/nejm200001203420301 · Cited by 8,663
Turner, R. C., Fox, C., Matthews, McElroy, H. H., Cull, C. A., Holman, R. R., Neil, P., Hadden, D. R., Wright, D., Manley, E., et al. (1998) · The Lancet · Cited by 8,419
Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus
The Expert Committee on the Diagnosis and Classification of Diabetes Mellitus (1997) · Diabetes Care · doi:10.2337/diacare.20.7.1183 · Cited by 6,220
Hansson, L., Zanchetti, A., Carruthers, S. G., Dahlöf, B., Elmfeldt, D., Julius, S., Ménard, J., Rahn, K. H., Wedel, H., & Westerling, S. (1998) · The Lancet · doi:10.1016/s0140-6736(98)04311-6 · Cited by 5,728
Research works printed but not linked: 3
- American Diabetes Association: Diabetes 2001 Vital Statistics. Alexandria, VA: American Diabetes Association; 2001.
- McFarlane S, Farag A, Sowers J: Hypertension. In Principles of Diabetes Mellitus. Edited by Poretsky L. Boston, MA: Kluwer Academic Publishers; 2002:671–683.
- Nateglinide and valsartan in impaired glucose tolerance outcome research: rationale and design of the NAVIGATOR trial. The NAVIGATOR Trial Steering Committee [no authors listed] [abstract]. Diabetes 2002, 51:A116.
Cited by
Diabetes, hypertension, and cardiovascular derangements: Pathophysiology and management
El-Atat, F., McFarlane, S. I., & Sowers, J. R. (2004) · Current Hypertension Reports · doi:10.1007/s11906-004-0072-y · Cited by 121
Self-citationShah, S., Iqbal, M., Karam, J., Salifu, M., & McFarlane, S. I. (2007) · Antioxidants & Redox Signaling · doi:10.1089/ars.2007.1629 · Cited by 115
Self-citationDietary advice for the prevention of type 2 diabetes mellitus in adults
Nield, L., Summerbell, C. D., Hooper, L., Whittaker, V., & Moore, H. (2008) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd005102.pub2 · Cited by 85
RetractedThe case for low carbohydrate diets in diabetes management
Arora, S. K., & McFarlane, S. I. (2005) · Nutrition & Metabolism · doi:10.1186/1743-7075-2-16 · Cited by 102
Self-citationAfter all those fat years: renal consequences of obesity
Wolf, G. (2003) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfg427 · Cited by 68
Metadata
- Authors
- McFarlane, S. I., Shin, J. J., Rundek, T., & Bigger, J. T.
- Affiliations
- State University of New York (US)
- Venue
- Current Diabetes Reports
- Published
- 2003-05
- Volume
- 3
- Issue
- 3
- Pages
- 235-241
- ISSN
- 1534-4827 (ISSN-L)
- 1539-0829
- OpenAlex
- W2103509869
- Cited by
- 28
- References
- 72
- Citations by year
- 2023: 1 · 2020: 1 · 2019: 1 · 2016: 1 · 2015: 1 · 2012: 1
- FWCI
- 0.85
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Current Diabetes Reports (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Keywords
- type 2 diabetes prevention, lifestyle modification, metformin, acarbose, high-risk patients, cardiovascular risk factors, diabetes complications, cardiovascular disease
- MeSH terms
- Adrenergic beta-Antagonists, Angiotensin-Converting Enzyme Inhibitors, Cardiovascular Diseases, Diabetes Mellitus, Type 2, Diabetic Angiopathies, Diet, Diabetic, Glucose Tolerance Test, Humans, Hypoglycemic Agents, Life Style, Exercise, Incidence
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Prevention of type 2 diabetes. https://app.cochat.ai/papers/10.1007/s11892-003-0070-5
- The paper
- McFarlane, S. I., Shin, J. J., Rundek, T., & Bigger, J. T. (2003). Prevention of type 2 diabetes. Current Diabetes Reports. https://doi.org/10.1007/s11892-003-0070-5
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.